Jiun-Hao Yu

Dr. Jiun-Hao Yu

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
JYJiun-Hao Yu
Jiun-Hao Yu
YWYi-Ming Weng
Yi-Ming Weng

27 February 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JYJiun-Hao Yu
Jiun-Hao Yu
PLPei-Ru Li
Pei-Ru Li
DCDong-Yi Chen
Dong-Yi Chen
WHWen-Kuan Huang
Wen-Kuan Huang
LSLai-Chu See
Lai-Chu See
In this research, we assessed mortality after major bleeding events in atrial fibrillation (AF) patients taking four direct oral anticoagulants (DOACs). Drawing data from the Taiwan National Health Insurance Research Database between 2016 and 2019, we focused on AF patients on DOACs who had major bleeding episodes. Using propensity score stabilized weighting, we established four comparable pseudo-DOAC groups. Among 2770 patients (460 dabigatran, 1322 rivaroxaban, 548 apixaban, 440 edoxaban), 85.3% were prescribed low-dose regimens. The 7-day mortality rate was 9.0%, surging to 16.0% by the 30th day. Compared with dabigatran, there was a distinct divergence in 7-day mortality of factor Xa inhibitors (p = 0.012), with hazard ratios of 1.83 (95% CI 1.11–3.00, p = 0.017) for rivaroxaban, 2.13 (95% CI 1.23–3.66, p = 0.007) for apixaban, and 2.41 (95% CI 1.39–4.19, p = 0.002) for edoxaban. This pattern remained consistent when analyzing the subgroup that received lower dosages of DOACs. In conclusion, factor Xa inhibitors were associated with a significantly higher risk of 7-day mortality following major bleeding events than dabigatran among AF patients.

1 November 2016 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
JYJiun-Hao Yu
Jiun-Hao Yu
DCDong-Yi Chen
Dong-Yi Chen
HCHsien-Yi Chen
Hsien-Yi Chen
KLKuo-Hua Lee
Kuo-Hua Lee

12 July 2022 in Toxics
Verified
Journal Article
Open access
PDF file
TYTzu hsin Yeh
Tzu hsin Yeh
HCHsien-Yi Chen
Hsien-Yi Chen
SLSung-Wei Liu
Sung-Wei Liu
TWTe-I Weng
Te-I Weng
CFCheng-Chung Fang
Cheng-Chung Fang
CLChih-Chuan Lin
Chih-Chuan Lin
Predictors of mortality in illicit drug users involving Novel Psychoactive Substances (NPS) and multiple substances have not been elucidated. We aimed to define predictors of mortality in the NPS endemic era’s illicit drug users to strengthen patient care in emergency treatment. This was a retrospective study. LC-MS/MS-confirmed positive illicit drug users who visited the emergency departments (ED) of six medical systems were enrolled. Demographic information, physical examinations, and laboratory data were abstracted for mortality analysis. There were 16 fatalities in 355 enrolled patients. The most frequently used illicit drugs were amphetamines, followed by opioids, cathinones, and ketamine. The most frequently detected cathinones among the 16 synthetic cathinones were eutylone, followed by mephedrone. The combined use of cathinones and ketamine was most commonly observed in our results. Univariate analysis revealed that the mortality patients were older, with deep coma, faster heart rate and respiratory rate, lower blood pressures and O2 room air saturation, more seizures, abnormal breath sounds, and had urine incontinence compared to the survivor patients. The mortality patients also had acute kidney injury, higher potassium, blood sugar, liver function test, and lactate level. The results of multiple logistic regression demonstrated that SBP < 90 mmHg, dyspnea, blood sugar > 140 mg/dl, and HCO3 < 20.6 mmHg were independent predictors of in-hospital mortality. Regardless of the pattern of the use of illicit drugs, the predictors allow for risk stratification and determining the optimal treatment.

1 June 2020 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
JYJiun-Hao Yu
Jiun-Hao Yu
CHChun-Fa Huang
Chun-Fa Huang
TWTe-Hao Wang
Te-Hao Wang
DHdong-zong Hung
dong-zong Hung
HMHan-Wei Mu
Han-Wei Mu
CPChi-Syuan Pan
Chi-Syuan Pan

3 October 2019 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
JYJiun-Hao Yu
Jiun-Hao Yu
JLJian‐Xun Lu
Jian‐Xun Lu
CSCraig Smollin
Craig Smollin
HCHao‐Tsai Cheng
Hao‐Tsai Cheng
Chen-June SeakChen-June Seak
Chen-June Seak
HCHsien‐Yi Chen
Hsien‐Yi Chen